Borage oil supplies an omega-6 fat the body converts into calming signaling molecules when omega-3 status cooperates. Strongest evidence is high-dose add-on for rheumatoid arthritis symptoms and lower doses for painful diabetic nerve symptoms. Reviews find no clear eczema benefit. Safety hinges on refined oil free of toxic plant alkaloids; risks include stomach upset and theoretical bleeding with blood thinners. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT / AST | Lower half of lab range (e.g., ALT roughly 10–25 U/L) | Screen for hepatic stress / PA-related injury |
| GGT | Toward lower half of reference | Sensitive to hepatic/biliary stress |
| Platelet count & CBC | Within lab reference | Baseline bleeding-risk context |
| PT/INR (if on warfarin) | Per anticoagulation clinic target | Detect INR shifts with oil co-use |
| HbA1c / fasting glucose | Individualized; often HbA1c <5.7% metabolic goal | Neuropathy outcomes track glycemic control |
| hs-CRP | Often <1.0 mg/L functional preference | Optional systemic inflammation trend |
| Omega-3 index (RBC EPA+DHA) | Often ~8–12% functional target | Guides co-supplementation strategy |
| Plasma or RBC GLA/DGLA (specialty) | Rise versus baseline on therapy | Confirms intake/incorporation |
Cadence: 8–12 weeks after reaching a stable dose, then every 6–12 months if continued long term—or sooner if symptoms of liver injury, bleeding, or intolerance appear